Now, let me write down my personal ratings and target prices for various stocks.

First is Tencent. My current target price for Tencent is 732+, which is the previous high. It is highly likely to be reached by the end of this year or next year. The ultimate target price is 1K+. It will become the first trillion-dollar stock in the East. After all, I believe Tencent would rank among the top three in the MAG7 even if it were listed in the U.S. market.

Next is Xiaomi. My target price for Xiaomi is 67+, expected to be achieved by the end of this year. Then, next year, the target price will be revised upward based on new narratives (robots + new cars). Robots are already in the pipeline; now it’s just a matter of seeing what new tricks Xiaomi can come up with.

Then there’s Alibaba. My initial target price for Alibaba is the previous high. The impact from the food delivery sector may lead to a contraction in Q3 operating revenue, but I believe this is a short-term negative. The 'Anti-Internal Competition' bill + accelerated AI deployment and the emergence of DS R2 will boost Alibaba’s AI valuation again. However, we must remain vigilant against Tencent.

SMIC and Huahong Semiconductor: The current narrative is about breaking through in the semiconductor sector + domestic substitution. SMIC is targeting the previous high, while Huahong, with its smaller market cap, is more suitable for call options and will rise much faster than SMIC. My current target price for Huahong is around 60.

BYD, honestly, I’m a bit speechless—it’s currently the second-largest loss-maker. The target price is set around 150. For BYD, I’m currently looking at overseas data + the outlook for premium cars. I have to say, the Yangwang U8L is really cool. I hope BYD goes bankrupt so I can take one home for 39.8.

ICBC: For now, it’s just fixed deposits. I’ll hold off until a good opportunity arises, then sell ICBC and go all in.

Jingtai Holdings: My initial target price is the previous high. Small-cap stocks are easy to pump. Right now, the East is heavily promoting innovative drugs. Those who invested in innovative drug funds this year are already rolling in profits. A quick glance at the comments suggests it’s a gastric cancer-specific drug? Didn’t look into it in detail—I’ll check with people in the industry later. If there’s an opportunity, I’ll go all in again.

$TENCENT(00700.HK) $XIAOMI-W(01810.HK) $BABA-W(09988.HK) $SMIC(00981.HK) $HUA HONG SEMI(01347.HK) $BYD COMPANY(01211.HK) $ICBC(01398.HK) $XTALPI(02228.HK)